The survival of cancer patients diagnosed 1966-2015 in the Nordic countries

NORDCAN shows 1- and 5- year age-standardised relative survival 1967-2016 by 5-year calendar year of diagnosis, cancer entity, country and sex for Denmark, Finland, Iceland, Norway and Sweden. For breast and prostate cancer 10-years survival is also shown. The International Cancer Survival Standards are used for age-standardisation. See the Glossary of terms in NORDCAN for more detailed description. Cohort survival methods are generally used  but for the later periods where not all patients could be followed  up for the full period, hybrid methods were used, supplementing with survival experience for patients diagnosed earlier years.

Five-year survival for the years 1964-2003 was first calculated in the Nordic Cancer Survival Study. This project was published in Acta Oncologica 2010 issue 5 in 13 papers. Papers can freely be downloaded and a list of the papers and links via PubMed can be found here.

The Acta Oncologica publication was a joint effort authored and co-authored by researchers from each Nordic country and presents highly comparable data in 13 individual peer reviewed papers, by organ groups and sites and for all sites combined including the importance of case-mix adjustment. Excess mortality was also studied in shorter time periods after diagnosis, and it is of note that most of the differences in survival and levels of the 5-year relative survival could be predicted from the excess mortality during the first 3 month after the cancer is diagnosed. With the exception of prostate and breast cancer, we found almost parallel trends in survival during the period of observation, and thus hypothesized that much of the differences seen in survival is related to life style factors, late presentation, and lack of screening, in particular for the Danish population.


Nordcan on the web

Version 8.2

Updated March 2019